| |
Volume
1, Number 2 |
August
2005
|
|
|
Inside
This Issue
|
|
|
|
Click
Here if you are having
problems viewing the newsletter.
|
PRESIDENT'S
MESSAGE
Welcome to the second ORS
Newsletter. We are very excited and honored to be able to send you our
Newsletter. The first Newsletter was met with overwhelming acceptance,
with numerous positive comments. Our goal is to further the knowledge
of vitreal and retinal disease to our colleagues and brethren. To that
aim, I believe that we have been successful.
Be sure to mark your calendars for March 24-26, 2006, for the 3rd annual
meeting of the ORS. It will be in the Theatre District in Boston, which
is a historic area downtown with plenty of attractions and restaurants
within walking distance.
Sincerely,
William L. Jones, O.D.
President
FROM
THE DESK OF THE EDITOR
This is a very exciting time to be interested in
retinal disease, particularly age-related macular degeneration. Several
years ago, before the approval of Photodynamic Therapy in April 2000,
we had very little in the way of options to offer our patients with ARMD.
Now, with Macugen, the first Anti-VEGF medication approved for the treatment
of Neovascular ARMD in December 2004, we have more options. Further, with
other medications on the horizon, such as Lucentis, Avastin and Anecortave
Acetate, we will have even more options for our patients in the not-so-distant
future. These treatments, combined with our ever-increasing knowledge
of gene therapy and modes of prevention, all add up to an exciting time
in research for macular degeneration.
Steven Ferrucci, O.D., F.A.A.O.
Editor in Chief
|
IMPORTANT:
DATE CHANGE
The date of the Third Annual ORS Conference has been changed to
March 24-26, 2006, in Historic Boston MA. The theme of this program
will remain Retinal Manifestations of Vascular and Related Systemic
Disease, and will focus on vascular diseases, such as diabetes,
and how they affect the retina.
Stay tuned for more information!!
|
YOU
MAKE THE DIAGNOSIS
Answer appears later in newsletter.
|
CLINICAL
PEARLS
Tips
for Better Stereoscopic Fundus Exam of the Macula
By Leo P. Semes, O.D., F.A.A.O.
For better stereoscopic appreciation when examining the retina, I use
a lower power dioptric lens. I started doing this when the 14D lenses
from Nikon were popular over 25 years ago and evaluation of the optic
nerve could be enhanced with BIO. The alternative at the time was the
Hruby lens which certainly had its limitations, but offered great stereo
of the optic nerve head. The contemporary version, of course, is a 60D
at the slit-lamp through a dilated pupil. If you are having trouble appreciating
nerve-head contour with a 90 D, try the 60D. The only price to be paid
for this clinically is that you need a well-dilated pupil. The 90 D and
its big brother the Superfield still give a good monocular access through
an undilated pupil. The only price to be paid for using the 60D is that
the pupil must be well dilated.
Not
All Retinal Disorders are Detectable with Ophthalmoscopy
By Jerome Sherman, O.D., F.A.A.O.
Recently, I evaluated a 29 yo Asian female who was referred because
of a 2 month complaint of a zone of blurred vision in her left field
through her left eye. She also reported light flashes or an "afterimage"
in the same eye. Several previous exams revealed normal and equal
VA, normal pupils, IOPs of 16 OU and a fundus described as "perfect."
My exam was in agreement. One previous visual field revealed a temporal
reduction in sensitivity OS but the loss did not respect the vertical
meridian. The differential diagnosis included an occult (or hidden)
retinal disorder, an optic nerve/visual pathway disorder and even
hysteria or malingering. I started at the retina and obtained a
flash electroretinogram. The amplitude was reduced in the left eye
under all scotopic and photopic conditions tested by as much as
50%. The late Donald Gass, MD, coined the term Acute Zonal Occult
Outer Retinopathy (AZOOR) for such a presentation. In a long term
follow-up of 51 cases (AJO 2004; 887-889), Gass noted that the mean
delay in diagnosis was 17 months. We have seen several other cases
with the longest delay in diagnosis of over 9 years. Interestingly
the patient with the delay of over 9 years had several normal MRIs
during that decade. Occult retinal disorders such as AZOOR should
be considered in the differential diagnosis of such patients. In
retinal disease, structure does not always match function.
|
JOURNAL
ABSTRACTS
Michels S, Rosenfeld PJ, Puliafito CA,
et al. Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related
Macular Degeneration Twelve-Week Results of an Uncontrolled Open-Label
Clinical Study Ophthalmology. June 2005; Vol.112,6:1035-1047.
Reviewed by James Fabian, O.D., Optometric Resident, Bascom Palmer
Eye Institute
This study was designed to evaluate the short-term safety of systemic
bevacizumab (Avastin) and its effects on VA and subfoveal CNV in patients
with neovascular AMD. Nine AMD patients with subfoveal CNV were treated
at baseline with an infusion of bevacizumab (5 mg/kg), followed by 1 or
2 additional doses given at 2-week intervals. Ophthalmologic evaluations
included protocol VA measurements and ocular examinations, along with
OCT, FA and IGA. There were no serious ocular or systemic adverse events
identified. By 6 weeks, the only adverse event identified was a mild elevation
of systolic blood pressure +12 mmHg, and this elevation was controlled
by either changing or initiating antihypertensive medication. Overall,
bevacizumab therapy was well tolerated, with an improvement in VA, OCT
and angiographic outcomes. Although these preliminary results are promising,
a randomized controlled clinical trial is necessary before concluding
that systemic bevacizumab therapy is safe and effective for patients with
neovascular AMD.
Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term Follow-up Results
of a Pilot Trial of a Fluocinolone Acetonide Implant to Treat Posterior
Uveitis. Ophthalmology. July 2005; Vol.112,7:1192-1198.
Reviewed by James Fabian, O.D., Optometric Resident, Bascom Palmer
Eye Institute
This article reveals the results of a long-term prospective study of the
fluocinolone acetonide sustained drug delivery implant to treat patients
with severe chronic noninfectious posterior uveitis. Thirty-six eyes of
32 patients were randomized to receive either a 0.59-mg or a 2.1-mg fluocinolone
acetonide intravitreal implant. Mean baseline visual acuity for the device-implanted
eyes was 20/250, which improved significantly to 20/125 at 30 months.
Inflammation was effectively controlled over the follow-up period. Over
the entire follow-up period, only 5 recurrences were recorded in the device-implanted
eyes. The posterior sub-Tenon’s capsule injection rate significantly
decreased from a mean of 2.2 injections per eye per year to 0.07 injections
per eye per year. Systemic meds were also reduced. The most common adverse
events were IOP rise and cataract. This therapy seems to be promising
in patients with posterior uveitis who do not respond to or are intolerant
to conventional treatment.
Cahill MT, Mruthyunjaya P, Richman CB, Toth CA. Recurrence of retinal
pigment epithelial changes after macular translocation with 360 peripheral
retinectomy for geographic atrophy. Arch Ophthalmol. 2005;123:935-938.
Reviewed by Noemi Zubizarreta, O.D., Optometric Resident, Bascom Palmer
Eye Institute
Originally, macular translocation with 360 peripheral retinectomy (MT-360)
was intended to relocate part of the retina away from a neovascular net,
in "wet" ARMD, to an area of unaffected retinal pigment epithelium.
This study was conducted in order to see if the same procedure could be
applied successfully to eyes with geographic atrophy (GA) secondary to
"dry" ARMD. Post-operative visual status and recurrence of GA
was assessed. In total, 75% of eyes treated with MT-360 for GA in
dry ARMD had a recurrence of RPE atrophy, which subsequently progressed
to GA, in the area of translocated retina, and, thus showed no recovery
of visual potential. This compares to only 8.3% recurrence of RPE
atrophy in eyes treated with MT-360 for neovascular ARMD. Further investigation
is aimed at determining whether GA is a result of RPE degeneration that
then leads to retinal photoreceptor atrophy, or if there is an inherent
defect in the photoreceptors themselves, which leads to atrophy of the
underlying RPE. The latter being true would suggest that MT-360 would
not be a viable treatment option for patients with visual loss secondary
to GA in dry ARMD and help explain the unsuccessful results of this study.
Agarwal A, Patel P, Adkins T, Gass D. Spectrum of pattern dystrophy
in pseudoxanthoma elasticum. Arch Ophthalmol. 2005;123:923-928.
Reviewed by Noemi Zubizarreta, O.D., Optometric Resident, Bascom Palmer
Eye Institute
Pseudoxanthoma elasticum (PXE) is a hereditary connective tissue disorder
that affects the skin, eyes and cardiovascular system. Ocular findings
include optic nerve drusen, peau d’orange RPE changes, angioid streaks
and pattern dystrophy of the macula. Pattern dystrophy is an autosomal
dominant dystrophy of the macula which is subdivided into 5 groups: reticular
dystrophy, fundus flavimaculatus, fundus pulverolentus, butterfly dystrophy
and vitelliform dystrophy. This study was aimed at describing the prevalence
and type of pattern dystrophy found in patients with PXE. Fluorescein
angiography was used to differentiate among the types of pattern dystrophy.
Of the 22 patients used in the study, 16 showed signs of pattern dystrophy.
The most common pattern dystrophy found was fundus pulverolentus, followed
by butterfly dystrophy. Only 1 patient each had fundus flavimaculatus
and reticular dystrophy. A single vitelliform lesion was found in only
1 eye of 1 patient. As an aside, all of the patients studied had angioid
streaks in their posterior poles.
Parodi MB, Boscia F, Piermarocchi S, Ferrari
TM, Furino C, Sborgia C. Variable outcome of photodynamic therapy for
choroidal neovascularization associated with choroidal nevus. Retina
2005;25:438-442.
Reviewed by Jeffrey S. Huang, O.D., Optometric Resident, Bascom Palmer
Eye Institute
Choroidal nevus (CN) associated choroidal neovascularization (CNV) were
treated with photodynamic therapy (PDT) with verteporfin in five patients
(5 eyes). All five cases of CNV were of the classic type, three of which
was juxtafoveal and two subfoveal. The CNV lesions were identified using
both fluorescein angiography (FA) and indocyanine green angiography (ICG).
Follow-up visits were scheduled at three-month intervals at which retreatment
using PDT was done if FA leakage persisted. The mean follow-up was 25.8
months. The number of PDT sessions needed to achieve CNV stabilization
varied from one to six. Final visual acuity varied widely from one case
resulting in 20/20 and two cases ending with 20/400.
The natural history and post-PDT outcome of subfoveal and juxtafoveal
CN associated CNV are highly variable. Further studies are necessary to
assess the real benefits of PDT in classis CNV secondary to CN.
Nazemi, PP, Wolfgang F, Lim JI, Sadun AA. Scotomas of age-related macular
degeneration detected and characterized by means of novel three-dimensional
computer-automated visual field test. Retina 2005;25:446-453.
Reviewed by Jeffrey S. Huang O.D., Optometric Resident, Bascom Palmer
Eye Institute
A recently developed computerized three-dimensional amsler grid was used
to detect and characterize scotoma of age-related macular degeneration.
Twenty-five patients (41 eyes) outlined their visual scotoma on a touch
sensitive computer screen. Patients outlined their scotoma in five different
contrast levels creating a three dimensional map of their hill of vision
for the central 25°. The results were compared to fundus photographs
and fluorescein angiograms.
Patients with nonexudative AMD demonstrated steep slopes while exudative
AMD presented with shallow slopes. Having the ability of plot the slope
of the scotoma may offer earlier detection of wet AMD compared to conventional
amsler grid. Furthermore, the method used in the study required only about
5 minutes per eye and potential worldwide access through the internet.
In summary, the new computerized amsler grid is comparable to the conventional
amsler in its ability to outline scotoma. However, it offers the unique
ability to define exudative versus nonexudative through the slope of the
scotoma.
Bandello F, Polito A, Del Borrello M, Zemella N, Isola M. "Light"
versus "classic" laser treatment for clinically significant
diabetic macular oedema. British Journal of Ophthalmolgy 2005;89:864-870.
Reviewed by Jeffrey S. Huang O.D., Optometric Resident, Bascom Palmer
Eye Institute
A prospective randomized pilot clinical trial comparing "light"
versus "classic" laser treatment for clinically significant
diabetic macular edema (CSME). "Light" laser was defined as
the lowest energy capable to produce barely visible burns of the retinal
RPE (ie: power ranging from 50mW and 100mW and an average of 92 spot).
"Classic" laser employed energy ranging from 100mW and 250mW,
and an average of 47 spots. Follow-ups were scheduled at three months-intervals
for 12 months with refraction, best-corrected visual acuity (BCVA), contrast
threshold, fundus biomicroscopy, fluorescein angiography (FA) and OCT.
Twenty-nine eyes (24 patients) were randomly assigned to "light"
laser (14 eyes) or "classic" laser (15 eyes). Study outcomes
at 3, 6 and 12 months between the two groups were not statistically significant
in retinal thickness measured by OCT, reduction of macular edema in contact
lens biomicroscopy and FA, vision loss, contrast sensitivity, and mean
deviation in the central 10° visual field. However, at 6 months,
"light" laser group had greater number of patients gaining 5
or more letters.
These results suggest that "light" photocoagulation for CSME
may be as effective as "classic" photocoagulation. This study
was limited by its small sample size.
Masahiko S, Kanako Y, Toru N, and Makoto T. Visual Dysfunction after
Panretinal Photocoagulation in Patients with Severe Diabetic Retinopathy
and Good Vision. American Journal of Ophthalmology July 2005;140:8-15.
Reviewed by Paul Collins, O.D., Optometric Resident, Bascom Palmer
Eye Institute
According to the recommendations of the ETDRS study group, PRP (pan retinal
photocoagulation) should be performed in eyes with severe diabetic retinopathy,
including those with severe non-proliferative and non-high-risk proliferative
diabetic retinopathy. Earlier studies have shown that 25% to 43%
of eyes with Proliferative Retinopathy treated with PRP develop macular
edema and visual disturbances. The results of this study provide some
answers towards the development of macular edema post-PRP, resulting in
transient or sustained VA decrease. The findings were that more than 80%
of eyes treated with PRP maintained pre-op VA, 5% had a transient
decrease, and 11% a sustained decrease at 6 weeks post-op. The limiting
factor of these three groups was parafoveal thickness demonstrated by
OCT. Those persons having pre-op parafoveal thickness of >300 microns
had a sustained decreased VA after PRP, all others with thickness <300
microns maintained pre-op VA at 6 weeks post-op. In summary, pre-op parafoveal
thickness should be performed before and post-PRP to indicate whether
post-op VA will be maintained.
|
ANSWER
TO "YOU MAKE THE DIAGNOSIS"
These lesions represent Idiopathic Sclerochoroidal Calcification
(ISC), representing calcium salt precipitation in the sclera and
choroid. ISC typically presents in white males between 50 and
80 years of age. These lesions are characteristically described
as yellow-white lesions underlying the retinal layers, typically
located bilaterally in the superotemporal arcade of the mid-peripheral
fundus, sometimes as mirror images of each other. They are usually
plaque like, with minimal elevation, but can present more tumor-like,
with elevation sometimes as much as 6 mm.
Patients with ISC are generally asymptomatic, with no effect on
visual acuity or visual field. Typically the lesions are found
on routine examination, and have not been associated with visual
loss due to their location away from the macula.
ISC can be misdiagnosed as various other choroidal lesions, most
notably choroidal melanoma or metastatic carcinoma. Therefore,
a careful systemic and ocular work-up is indicated to confirm
this diagnosis of exclusion.
Steven Ferrucci, O.D., F.A.A.O.
ORS Fellow
|
IN THE
NEWS
 |
Patients who received
a sustained-release fluocinolone acetonide implant had a significantly
lower rate of uveitis after implantation than in the year before
implantation, according to Bausch & Lomb. The need for adjunctive
therapy with steroids or immunosuppressant in the study eyes was
reduced by 2 years postop, from 52.5% to 12.5%, and the
need for periocular injection of steroids was reduced from 68%
to 9.7%. In the fellow eyes, the need for adjunctive therapy
increased from 30.4% prior to study enrollment to 45.3%
after study enrollment. The Retisert implant is expected to become
available this summer, according to Bausch & Lomb.
|
|
Treatment with pegaptanib
sodium was associated with regression of signs of diabetic retinopathy
and improvement on a scale of retinopathy severity, results of
a Phase 2 study showed. Imaging data from the Phase 2 study of
Macugen (pegaptanib sodium injection, Eyetech/Pfizer) for the
treatment of diabetic macular edema showed a reversal of capillary
microaneurysms, retinal ischemia and neovascularization, according
to a press release from Eyetech Pharmaceuticals. These early results
from the study were presented at the Association for Research
in Vision and Ophthalmology meeting.
|
|
Transpupillary thermotherapy
was associated with a significant clinical benefit in a subgroup
of patients with wet age-related macular degeneration in a clinical
trial comparing the laser treatment to sham treatment, according
to a press release from Iridex, the sponsor of the trial. At 12
months following treatment, 23% of the eyes treated with TTT
showed improvement of vision by one or more lines, and 14%
of eyes treated showed improvement of vision by three or more
lines. No eyes in the placebo group showed improvement. At the
18 month follow-up, there was a two-line benefit in preserving
vision in this subgroup compared with the placebo-treated eyes,
according to Iridex. On average, eyes treated with TTT lost two
lines of visual acuity while those on placebo lost four lines.
|
|
Preliminary analysis
of data showed that approximately 95% of patients receiving
Lucentis (ranibizumab, Genentech) maintained vision at 1 year,
according to a press release from Genentech. In the control arm
of the study, 62% of patients maintained vision. In addition,
patients treated with Lucentis had, on average, a significant
improvement in visual acuity compared to their visual acuity at
study entry. Control patients had a decrease in visual acuity
from baseline to 12 months.
|
|
Aggressive management
with chemotherapy and repeated laser applications resulted in
tumor control in a large percentage of patients with macular retinoblastoma,
according to a study presented at the Association for Research
in Vision and Ophthalmology meeting.
|
|
An angiostatic cortisene
developed for the treatment of wet age-related macular degeneration
has received an "approvable" letter from the Food and
Drug Administration, the drug’s developer said in a press
release. Retaane 15 mg (anecortave acetate suspension, Alcon)
is being assessed in clinical trials for "preserving the
vision of patients with wet AMD," according to the company.
Alcon will meet with the FDA to discuss the letter, the clinical
studies submitted with the new drug application and other ongoing
clinical studies to determine future steps to ensure final approval,
the company said in the release.
|
|
Macugen (pegaptanib
sodium injection, Eyetech Pharmaceuticals), an anti-vascular endothelial
growth factor (VEGF) therapy indicated for the treatment of all
subtypes of neovascular age-related macular degeneration, had
one of the most successful launches in the ophthalmic industry
and is on track to be in the top 10% of biotech and pharmaceutical
launches of the past 20 years, according to David R. Guyer, MD,
chief executive officer of Eyetech. Dr. Guyer and other officials
of Eyetech Pharmaceuticals, presented details about the Macugen
franchise and new therapies in the company’s pipeline here
at an event in New York called Eyetech Vision Day.
|
|
Nearly 8% of
people identified with "pre-diabetes" were classified
as having diabetic retinopathy, a report from the American Diabetes
Association said. In addition, diabetic retinopathy was seen in
12% of participants with type 2 diabetes, the association
said in a press release.
|
|
Two biomarkers for
cardiovascular disease have been found to be independently associated
with the progression of age-related macular degeneration, according
to Johanna M. Seddon, MD and colleagues. The study is published
in the June issue of Archives of Ophthalmology.
|
|
Two years of treatment
with Macugen (pegaptanib sodium for injection, Eyetech/Pfizer)
provided sustained benefit for patients with age-related macular
degeneration, according to a physician speaking in Montreal at
the American Society of Retina Specialists meeting. Donald J.
D’Amico, MD, said patients receiving pegaptanib had better
visual outcomes at the 2-year follow-up point than those who received
sham treatment. Of patients who completed Year 2 of Macugen treatment,
35% had the same visual acuity as at baseline or had improved
during the second year of treatment. Patients who were treated
with Macugen 0.3 mg for a second year showed a mean visual acuity
loss of 9.4 letters on an eye chart, compared with a loss of 17
letters in those who did not receive Macugen.
|
|
Central retinal thickness
was reduced in patients with age-related macular degeneration
as early as 1 day after treatment with Lucentis (ranibizumab,
Genentech), a VEGF-inhibiting drug, according to study results
reported at the American Society of Retina Specialists conference
in Montreal. Vision also improved in the patients by Day 14, a
speaker said. Anne E. Fung, MD, reported partial results of a
study in which 40 patients with subfoveal choroidal neovascularization
and central retinal thickness measurements of at least 300 µm
were treated with Lucentis.
|
MEET
THE FELLOWS
In each issue, a Fellow
of the Optometric Retinal Society will be highlighted. In this issue,
Dr. William Jones, President and one of the Founding Fellows
of the Optometric Retinal Society will be highlighted.
Following graduation from the University of Houston Optometry School,
Dr. Jones completed a residency at the Veterans Administration Medical
Center in Kansas City, Missouri. He later served as Chief of the Optometry
Section as well as director of the Optometry Residency Program at the
Albuquerque VA Medical Center for almost 20 years. Currently he is employed
at the Eye Institute of Albuquerque.
Dr. Jones is a frequent publisher and lecturer, with over 75 articles
published in the last 25 years, as well as several textbooks. His textbook,
Atlas of the Peripheral Fundus, 2nd Edition, was awarded as one
of the 250 Best Health Science Books for 1999 by Doody’s Journal
of Health Sciences. He is an internationally know lecturer, with hundreds
of lectures presented in the United States and abroad, with an emphasis
on retina and posterior pole. He also serves as a journal reviewer for
several optometric journals, and has been on several editorial boards.
Further, he is a consultant for OPTOS, as well as a former Lieutenant
Colonel, Medical Service Corp, in the US Army Reserves. He is currently
president of the Optometric Retinal Society, as well as one of the Founding
Fellows.
Dr. Jones resides in Albuquerque, New Mexico, with his wife, Siu Wong,
O.D., and daughter, Yung.
WHY
BECOME AN ORS MEMBER?
By Rex Ballinger, O.D., F.A.A.O.
Chair, Membership Committee
Membership in the Society can provide several benefits; 1.) You
may receive discounts at annual meetings. 2.) You’ll receive
regular newsletters on new and exciting updates on retinal disease
diagnosis and management as well as other newsy items of interest.
3.) You’ll be associated with a body of knowledge and resources
which can help you in many other ways. So consider membership
in the Society. It will be worth your while in your quest for
better understanding of the retina.
If your interests extend beyond the general, if you want to become
part of the dynamic team involved in the Society to share your
interest and enthusiasm with your colleagues consider becoming
a Fellow member. Details and applications can be found at www.optometricretinasociety.org
|
SPONSOR
NEWS
 ALCON
- ICaps L&Z and AREDS for Ocular Health
ICaps
Lutein & Zeaxanthin Eye Vitamin and Mineral Supplement is formulated
for people at risk of age-related eye conditions. This formula contains
all the high-potency antioxidants and zinc important to eye health,
plus the added benefit of lutein and zeaxanthin, the primary carotenoids
found in the retina and lens of the eye.
ICaps
AREDS Eye Vitamin and Mineral Supplement formula matches the combination
of vitamins and minerals established by the AREDS trial as effective
in delaying the progression of AMD.
For more information, go to www.icapsvitamins.com
 OFFICEMATE
- Retinal Examination and Documentation
Retinal examination and documentation couldn’t be easier and more
complete using ExamWRITER electronic health record. Finally, retinal
documentation, including specialized retinal imaging procedures such
as the Optomap Retinal Exam, and Visual Field testing like the Zeiss
Meditec HFA II i are both captured, stored and reviewed from within
the electronic patient chart via ExamWRITER’s seamless instrument
interface.
Designed exclusively as an eyecare medical program by eyecare professionals,
ExamWRITER integrates with OfficeMate software and enables doctors and
staff to fully document patients’ charts with effortless speed
by utilizing standardized controls and customizable templates that follow
the SOAP protocol.
ExamWRITER electronic health records brings a new level of efficiency
and accuracy into your practice by giving you the ability to create,
edit, store, and access complete and comprehensive patient exam records.
For additional information contact us at 800.269.3666 or visit our website
at www.officemate.net.
 OPTOS
- Multi-Center Study Concludes Optomap and BIO When Used in Tandem Provides
Improved Detection of Retinal Disorders
The results of an Optos sponsored study conducted at the University
of Houston, UC, Berkeley and Pennsylvania College of Optometry were
presented at the 2005 Association for Research in Vision and Ophthalmology
meeting (ARVO).
Both Standard (subject looking straight ahead) and Steered (subject
looking 15 degrees eccentrically at 12, 3, 6 and 9 o’clock positions)
Optomap Retinal Exams compare favorably with the BIO in detecting clinically
important abnormalities posterior to the equator. Both Optomap Standard
and BIO examination of the entire retina failed to detect a small but
significant percentage of findings compared to the referee gold standard
(when discrepancies between exams were noted, a referee examiner, performed
BIO and re-evaluated the Optomap Images). Given that the types of findings
missed were different between techniques, it is suggested that the combination
of Optomap with BIO provides improved detection of retinal abnormalities.
For more information, go to www.optos.com.
 VOLK’s
New Digital Wide Field Lens Balances Magnification and Field of View
When choosing a lens, doctors traditionally have had to choose between
wide field of view or high magnification. The Digital Wide Field lens
offers the widest field of view available in a non-contact lens, combined
with excellent small pupil capability and a .72x magnification--similar
to Volk’s popular 90D lens. The unique digital lens design and
coating reduce glare and reflections while maintaining high-resolution
images for improved retinal diagnosis and slit lamp photography. Like
most Volk lenses, the Digital Wide Field is constructed with patented
double-aspheric glass optics, resulting in an undistorted image across
the entire lens surface.
For more information, go to www.volk.com.
 ZEISS
- A Breakthrough in Early Detection of Wet AMD
The PreView PHP is a new perimeter used to detect recent-onset neovascular
(“wet”) AMD, and differentiate it from the intermediate (“dry”)
stage of the disease, often before signs or symptoms are noticed by
the patient or the doctor. Validated in multi-center clinical studies,
this new technology will allow earlier detection of the advanced, blinding
form of AMD, allowing treatment before the patient has suffered irreversible
vision loss.
For more information, go to www.meditec.zeiss.com.
|
Editor
in Chief
Steven Ferrucci, OD, FAAO
Co-Editor
Mark T. Dunbar, OD, FAAO
|
Journal
Reviewers
Paul Collins, OD
James Fabian, OD
Jeffrey S. Huang, OD
Noemi Zubizarreta, OD
Art/Production Director
Joe Morris
Circulation Director
Janice Miller
|
| This
paid, promotional message was sent to you by Jobson Professional
Publications Group. The content does not necessarily reflect the
views, or imply endorsement, of the Group's editors or publisher.
If you do not want to receive this type of information in the future,
simply reply to this message with the words "Unsubscribe Mailings"
in the subject header. Jobson Professional Publications never releases
its e-mail list. |
|
